Willis Towers Watson plc director Fredric J. Tomczyk reported a routine tax-related share disposition. On May 15, 340.635 ordinary shares were withheld by the company at $247.64 per share to cover taxes tied to the vesting and settlement of 709.655 restricted share units granted on May 15, 2025. After this withholding, he directly owns 1,347.020 ordinary shares, so this filing reflects compensation and tax treatment rather than an open-market trade.
Willis Towers Watson director Jacqueline Hunt reported a routine tax-related share withholding. On the vesting and settlement of 709.655 restricted share units granted on May 15, 2025, the issuer withheld 340.635 Ordinary Shares at $247.64 per share to cover taxes, leaving her with 1,347.020 shares directly owned.
Willis Towers Watson director Paul C. Reilly reported a tax-withholding disposition of shares tied to restricted share unit vesting. On May 15, 2026, 495.468 ordinary shares were withheld at $247.64 per share to cover taxes related to the vesting and settlement of 1,032.225 restricted share units granted on May 15, 2025. After this non-market transaction, he held 1,827.757 ordinary shares directly and 48 ordinary shares indirectly through a revocable trust.
Willis Towers Watson director Stephen M. Chipman reported a routine tax-related share disposition. On May 15, 2026, 340.635 ordinary shares were withheld by the company at $247.64 per share to cover tax obligations tied to vesting restricted share units. Following this withholding, he directly holds 1,347.020 ordinary shares. The footnote explains this was connected to the vesting and settlement of 709.655 restricted share units granted on May 15, 2025, indicating a compensation and tax event rather than an open-market sale.
Willis Towers Watson PLC director Michelle R. Swanback disposed of 340.635 ordinary shares through a tax-withholding arrangement tied to equity compensation. The shares were withheld by the company at a price of $247.64 per share to cover taxes on the vesting and settlement of 709.655 restricted share units granted on May 15, 2025. After this non-market transaction, she holds 1,923.020 ordinary shares directly.
Willis Towers Watson plc director Fumbi F. Chima reported a routine tax-related share withholding. On May 15, 2026, 534.177 ordinary shares were withheld at $247.64 per share to cover taxes tied to the vesting and settlement of 1,112.867 restricted share units granted on May 15, 2025. After this non-market disposition, Chima holds 2,897.690 ordinary shares directly.
Willis Towers Watson PLC executive Lucy Clarke, President of Risk & Broking, purchased 1,896 Ordinary Shares in an open-market trade at $263.365 per share. Following this transaction, she directly owns 22,717.453 Ordinary Shares of the company.
Willis Towers Watson PLC Chief Executive Officer Carl Aaron Hess reported an open-market purchase of 2,000 Ordinary Shares on 2026-05-04 at $255.08 per share. Following this transaction, his direct ownership increased to approximately 117,425 Ordinary Shares.
Willis Towers Watson posted solid first‑quarter growth with active deal activity. Revenue for the three months ended March 31, 2026 rose to $2.41 billion from $2.22 billion a year earlier, driven by both Health, Wealth & Career and Risk & Broking.
Profitability improved. Net income attributable to WTW increased to $297 million from $235 million, and diluted earnings per share climbed to $3.10 from $2.33. The effective tax rate fell to 18.6% from 21.5%, helped by a discrete UK tax benefit.
Cash flow and balance sheet shifted due to acquisitions and refinancing. Operating cash flow was a modest outflow of $10 million, while total cash, cash equivalents and restricted cash fell to $5.41 billion after $840 million used in investing, including the $1.05 billion Newfront Insurance Holdings acquisition. Long‑term debt rose to $6.30 billion, including a $550 million draw on a new delayed draw term loan used to repay $550 million of 4.400% senior notes due 2026.
Willis Towers Watson reported solid first-quarter 2026 growth with stronger profitability. Revenue rose 8% to $2.41 billion, with 3% organic growth, while net income increased 27% to $303 million. Diluted EPS grew 33% to $3.10 and adjusted diluted EPS rose 19% to $3.72, reflecting operating discipline.
Operating margin was 18.6%, down 80 bps, but adjusted operating margin improved 70 bps to 22.3% as cost controls and efficiency gains offset higher transaction and integration expenses. Health, Wealth & Career and Risk & Broking each delivered 9% reported revenue growth and 60 bps margin expansion.
Free cash flow remained negative at $(65) million, though it improved by $21 million year over year. The company repurchased $300 million of shares and paid $88 million in dividends, and it targets continued annual margin expansion, higher free cash flow margins and at least $1.0 billion of 2026 share repurchases, alongside the Newfront acquisition and the Willis Re joint venture effects on earnings.